Special Report: The New Science of Haemophilia

A flow of ideas to stop the bleeding

Join Our Community of Science Lovers!

In any complex machine, the lack of a single part can lead to big trouble. That is the problem faced by the 170,000 people globally who have the bleeding disorder known as haemophilia. A genetic mutation (usually inherited) suppresses the production of proteins that make blood coagulate. Internal bleeding into the joints causes bone degradation and excruciating pain, and even mild injuries can be life-threatening.

The standard therapy is frequent infusions with blood-clotting promoters. These treatments are uncomfortable and expensive, so it is welcome news that several longer-lasting clotting factors have been developed. Many people develop an immune resistance to these infused factors, but relief may be on the way in the form of anti-inhibitory pills made from plants. Development of these pills depends on colonies of haemophilic dogs that serve as cooperative test subjects.

Clotting-factor infusions treat symptoms of haemophilia, but gene therapy could provide a cure. Research is also moving ahead on an alternative treatment strategy to remove or disable the body's anticoagulants rather than adding clotting factors.

On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.

The haemophilia community is still haunted by the traumas of blood supplies that were contaminated with HIV and hepatitis C. These experiences have led to reluctance to accept the good news that may soon be on offer, says medical historian Stephen Pemberton.

This Outlook, which is being published in Scientific American and Nature, is sponsored by Baxter Healthcare Corporation. It was produced independently by editors of Nature, who have sole responsibility for all editorial content. Beyond the choice to sponsor the particular topic of haemophilia, Baxter Healthcare Corporation had no input into the editorial content of this package.

This article is reproduced with permission and was first published on November 26, 2014

Subscribe to Support Independent Journalism

Great science journalism requires human expertise, time, effort and creativity. And it costs money. That’s why I and the journalists here at Scientific American hope you’ll join our community.

When you subscribe, you are supporting staff and freelance journalists who are passionate about telling science stories that are true, important and compelling. Our editors and reporters are often experts in their fields, which means they understand the nuances of big discoveries and can untangle the breakthroughs from the hype. With a subscription, you are also supporting rigorous fact-checking to ensure the words we publish are precise and accurate. And you’re supporting original illustrations, graphics and photos that bring you closer to an advanced laboratory, an ice sheet in Antarctica or a space mission in orbit. You’re helping us craft other types of high-quality journalism as well: Our newsletters are carefully written, edited and curated by staffers you have or will come to know and love. Our Science Quickly podcast is based on original reporting, collaboration with editors and scientists and exacting production.

Subscriptions keep this engine running so we can continue to deliver thoughtful, rigorous and independent science journalism to you. In an era of viral misinformation, this work is crucial. If you value what we do, I hope you’ll consider joining us as a subscriber

Thank you,

Jeanna Bryner, Editor in Chief, Scientific American